Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs

Description: Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.

The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients.

As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.

Scope

- What is the pathophysiology of gastric cancer?
- How is gastric cancer diagnosed?
- What are the current treatment options?
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
- What implications will the increased focus on targeted therapies have on the future of gastric cancer treatment?
- What are the most promising first-in-class targets for gastric cancer?
- Will the current first-in-class targets have a broader therapeutic potential across the industry?
- How do deal frequency and value compare between target families and molecule types?
- How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies
- Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals and producing a list of gastric cancer therapies that are not yet involved in deals, and may be potential investment opportunities.

Contents:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Significant Unmet Needs in the Gastric Cancer Market
2.2 High Proportion of First-in-Class Innovation Offers Promise in Gastric Cancer
2.3 Deal Activity Varies with First-in-Class Status
8.3.2 Co-development Deals by Molecular Target
8.3.3 Conclusion
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals

9 Appendix
9.1 References
9.2 Abbreviations
9.3 Research Methodology
9.4 Secondary Research
9.4.1 Marketed Product Heatmaps and Treatment Algorithm
9.4.2 Pipeline Analysis
9.4.3 First-in-Class Matrix Assessment
9.4.4 First-in-Class Target Profiles
9.4.5 Licensing and Co-Development Deals
9.5 Contact Us
9.6 Disclaimer

1.1 List of Tables
Table 1: Gastric Cancer, Tumor, Node and Metastasis Staging
Table 2: Gastric Cancer, Key Features and Pipeline Activity of HER 3
Table 3: Gastric Cancer, Key Features and Pipeline Activity of ATM
Table 4: Gastric Cancer, Key Features and Pipeline Activity of L1CAM
Table 5: Frequency of Mutations in Components in Akt Proteins, by Cancer Type
Table 6: Gastric Cancer, Key Features and Pipeline Activity of AKT 1
Table 7: Gastric Cancer, Key Features and Pipeline Activity of AKT 2
Table 8: Gastric Cancer, Key Features and Pipeline Activity of AKT 3
Table 9: Gastric Cancer, Key Features and Pipeline Activity of FGFR-3
Table 10: Gastric Cancer, Key Features and Pipeline Activity of PDPK1
Table 11: List of Abbreviations

1.2 List of Figures
Figure 1: Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987-2012
Figure 2: First-in-Class and Non-First-in-Class Products, Sales Performance After Marketing Approval ($m)
Figure 3: Gastric Cancer, Heatmap for First-Line Marketed Products
Figure 4: Gastric Cancer, Heatmap for Second-Line Therapy Marketed Products
Figure 5: Gastric Cancer, Overview of Marketed Products
Figure 6: Gastric Cancer, Overview of Pipeline Products
Figure 7: Gastric Cancer, Molecular Targets in Pipeline
Figure 8: Gastric Cancer, Pipeline by Molecular Targets and Stage of Development
Figure 9: Gastric Cancer, Molecular Target Family Comparison, Pipeline and Marketed Products
Figure 10: Gastric Cancer, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets
Figure 11: Gastric Cancer, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%)
Figure 12: Gastric Cancer, Percentage of First-in-Class Products in Pipeline by Stage of Development (%)
Figure 13: Gastric Cancer, First-in-Class Products in Pipeline (Part 1)
Figure 14: Gastric Cancer, First-in-Class Products in Pipeline (Part 2)
Figure 15: Gastric Cancer, First-in-Class Products in Pipeline (Part 3)
Figure 16: Gastric Cancer, Target Matrix Assessment (Part 1)
Figure 17: Gastric Cancer, Target Matrix Assessment (Part 2)
Figure 18: Gastric Cancer, Programs Targeting HER 3
Figure 19: Gastric Cancer, Programs Targeting ATM
Figure 20: Gastric Cancer, Programs Targeting L1CAM
Figure 21: Gastric Cancer, Programs Targeting AKT 1
Figure 22: Gastric Cancer, Programs Targeting AKT 2
Figure 23: Gastric Cancer, Programs Targeting AKT 3
Figure 24: Gastric Cancer, Programs Targeting FGFR 3
Figure 25: Gastric Cancer, Programs Targeting PDPK1
Figure 26: Gastric Cancer, Deals by Stage of Development, 2006-2014
Figure 27: Gastric Cancer, Licensing Deal Values by Stage of Development ($m), 2006-2014
Figure 28: Gastric Cancer, Licensing Deal Value, 2006-2015
Figure 29: Gastric Cancer, Licensing Deals by Year, 2006-2015
Figure 30: Gastric Cancer, Licensing Deals by Stage of Development, 2006-2015
Figure 31: Gastric Cancer, Licensing Deal Value by Stage of Development and Molecule Type, 2006-2015
Figure 32: Gastric Cancer, Licensing Deal Value by Molecular Target, 2006-2015
Figure 33: Gastric Cancer, Summary of Licensing Deals, 2006-2015
Figure 34: Gastric Cancer, Co-development Deal Value, 2006-2015
Figure 35: Gastric Cancer, Co-development Deals by Year, 2006-2015
Figure 36: Gastric Cancer, Co-development Deals by Stage of Development, 2006-2015
Figure 37: Gastric Cancer, Co-development by Stage of Development and Molecule Type, 2006-2015
Figure 38: Gastric Cancer, Co-development by Stage of Development and Molecular Target, 2006-2015
Figure 39: Gastric Cancer, Summary of Co-development Deals, 2006-2015
Figure 40: Gastric Cancer, First-in-Class Therapies Not Involved in Deals (Part 1)
Figure 41: Gastric Cancer, First-in-Class Therapies Not Involved in Deals (Part 2)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3692270/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs
Web Address: http://www.researchandmarkets.com/reports/3692270/
Office Code: SCD2I69E

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 6995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 13990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 20985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: _____________________________ Last Name: _____________________________
Email Address: * _____________________________
Job Title: _____________________________
Organisation: _____________________________
Address: _____________________________
City: _____________________________
Postal / Zip Code: _____________________________
Country: _____________________________
Phone Number: _____________________________
Fax Number: _____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World